Alembic Pharmaceuticals Limited has officially announced the incorporation of a wholly-owned subsidiary in Thailand, named Alembic Pharmaceuticals (Thailand) Co., Ltd. The primary objective of this new entity is to explore and establish new business opportunities for the promotion, sale, and distribution of the Company’s pharmaceutical products within the Southeast Asian geography. The subsidiary has commenced with a share capital of Three Million Baht, though it is yet to commence business operations.
Expansion into Southeast Asia Confirmed
Alembic Pharmaceuticals Limited has taken a strategic step towards international expansion by confirming the incorporation of a new subsidiary. This entity, named Alembic Pharmaceuticals (Thailand) Co., Ltd., is established in Thailand, marking the Company’s entry into the Southeast Asian market. The announcement was made on March 9, 2026.
Subsidiary Details and Capitalization
The newly incorporated subsidiary operates within the Pharmaceuticals industry. The entity’s initial Share Capital is set at 3,000,000.00 Baht (Three Million Baht Only), which is divided into 300,000 shares with a face value of Baht 10 each. It is noted that the subsidiary has Nil turnover as it is yet to commence business operations.
Strategic Rationale and Ownership
The primary objective for establishing the Thai subsidiary is To explore new business opportunities in the region, specifically focusing on the promotion, sale, and distribution of Alembic’s pharmaceutical products. This move falls directly within the main line of business for the listed entity. Alembic Pharmaceuticals Limited holds a substantial controlling stake, securing 99.99% of the shareholding in the new foreign subsidiary.
The consideration for this incorporation was an Investment in Share capital of the Company, rather than a cash or share swap transaction.
Source: BSE
